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5AC = 5-aza-2′-deoxycytidine; 5-FU = 5-fluorouracil; ALL = acute lymphoblastic leukaemia; AML = acute myeloid leukaemia; BAC = bacterial artifi-
cial chromosome; bp = base pair; CGH = comparative genomic hybridisation; CsA = cyclosporin A; DLBCL = diffuse large B-cell lymphoma;
DPYD = dihydropyrimidine dehydrogenase; ER = oestrogen receptor; EST = expressed sequence tag; FISH = fluorescence in situ hybridisation;
HIV = human immunodeficiency virus; HNSCC = head and neck squamous cell carcinoma; JNK = Jun N-terminal kinase; LCM = laser capture
microdissection; LDR = ligase detection reaction; Mb = megabase (1 million bases); NC160 = National Cancer Institute’s set of 60 human cancer
cell lines; PCR = polymerase chain reaction; RDA = representational difference analysis; SAPK = stress-activated protein kinase; SSH = supres-
sion subtractive hybridisation; TPA= phorbol ester; Top1 = topoisomerase 1; Top2 = topoisomerase 2.
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Introduction
The Human Genome Project, which is nearing completion,
is expected to lead to the identification of up to 50,000
human genes. The key question now facing the cancer
community is how to use information from this project for
the benefit of cancer patients. One of the key technical
platforms that has been developed to achieve this is
microarray analysis. This review highlights the ways in
which DNA microarray technology can be utilised in a
wide range of approaches to aid drug discovery and
development and to improve our understanding of the
mechanism of cancer development. Where possible, the
work will focus on breast cancer, but other cancers will be
described to illustrate particular approaches that may be
of relevance to breast cancer. Many new bioinformatics
approaches are being developed to support the analysis
of the large amount of data generated by microarray
studies. It is not the intention of this review to focus on
bioinformatics, however, as information on this important
area can be obtained from a number of sources (see [1]).
Microarray design
A microarray is an orderly arrangement of known or
unknown DNA samples attached to a solid support. Each
DNA spot on the microarray (called the probe) is usually
less than 200 µM in diameter and an entire array typically
contains thousands of spots. Many different design
formats are possible [2]. The probes attached to the solid
support can be small oligonucleotides, cDNAs or genomic
sequences. The array may be formatted by photolitho-
graphic synthesis of oligonucleotides in situ [3–5], or the
DNA samples may be applied directly to the array surface
by pins, nibs or inkjet technology [6–8]. Several distinct
chemistries may be used to attach the probe to the
surface, and hybridisation may be electronically controlled
[9]. The target sequence hybridised to probes on the array
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may be radioactively or fluorescently labelled. Despite the
large number of possible permutations, only a small
number of formats are in common use.
Filter arrays
Filter arrays are produced by the high-density application of
DNA samples, usually cDNAs, to nylon hybridisation mem-
branes such as those used for Southern analysis [10–12].
Filter arrays have the advantage that they are commercially
available and require no specialised equipment. Their use
may be appropriate if only small RNA samples are available,
as a result can be obtained with as little as 50 ng total RNA,
which is used in reverse transcription reactions to synthe-
sise a radiolabelled probe (usually with 32P or 33P). There
are, however, several major disadvantages to this approach.
First, the hybridisation patterns of two different targets can
only be compared by comparing the results obtained with
duplicate files or following stripping and rehybridisation of
the same filter. This system is also generally thought to be
less sensitive than other formats, detecting only high- and
medium-abundance transcripts. An example of a result
obtained with a filter array is shown in Figure 1.
Glass DNA microarrays
Glass DNA microarrays are produced by the robotic appli-
cation of DNA to a glass surface; cDNAs or genomic
clones are usually applied [6,7], although oligonucleotides
may also be used [13]. This approach has the advantage
that the probe can be covalently attached to an appropri-
ately treated glass surface. Glass is extremely durable and
its non-porous properties mean that both the access of
the hybridisation target to attached probes and the
washing steps are rapid and highly reproducible. In addi-
tion, the transparency and rigidity of glass improves image
acquisition, and its low-fluorescence background results
in superior sensitivity. As the target or test samples are flu-
orescently labelled, several targets can be hybridised
simultaneously in a single reaction, allowing direct com-
parison between samples. A disadvantage of glass DNA
microarrays is that large target samples are required:
probes would typically be prepared from 1–5 µg poly(A)+
RNA or 50–200 µg total RNA by reverse transcription
under conditions that allow incorporation of one of two flu-
orescently labelled dyes designated Cy3 (red) and Cy5
(green). Alternatively, if DNA sequences are under investi-
gation, the same dyes may be incorporated into genomic
DNA by random priming. Technical details for the fabrica-
tion of arrays are provided by Southern et al [14], Cheung
et al [15] and at the websites listed in Table 1.
High-density oligonucleotide arrays
In this format, arrays of oligonucleotides (20–25mers) are
synthesised in situ on a flat solid support [5,16–19].
Affymetrix achieves this by first attaching linkers containing
a photochemically removable protecting group to a glass
surface. Selected areas of the surface are then activated
by illumination through a photolithographic mask, yielding
reactive hydroxyl groups. A given nucleotide (A, G, C or T)
is incubated with the surface under conditions that allow
attachment of a single nucleotide only to the areas illumi-
nated in the previous step. Repeating this process using a
series of photolithographic masks that each direct light to
different areas of the surface allows the synthesis of a large
number of distinct oligonucleotides (Figure 2). Any set of
oligonucleotides of length N can be synthesised in a
maximum of 4 × N cycles. This approach has many of the
advantages of the glass DNA arrays described above and
allows much higher densities of probe. For example,
Affymetrix typically produces arrays, called GeneChips,
that contain at least 300,000 different oligonucleotides in a
1.28 × 1.28 cm area. Another advantage of this approach
is that the high information density allows the use of probe
redundancy to check results and provides an extensive
series of controls. Disadvantages of this format are that
careful development is required to produce a single reliable
microarray, and it is not possible to produce custom-built
arrays rapidly. For some applications, hybridisation of only
one labelled target to the array is recommended, which
prevents direct comparison between two samples in a
single experiment. The arrays are also expensive, limiting
access by academic institutions.
Image analysis
Filter arrays hybridised to radiolabelled targets can be
monitored by phosphorimager systems. Glass DNA
arrays and high-density oligonucleotide arrays hybridised
Figure 1
Filter microarrays hybridised to [α-33P]-labelled cDNA probes prepared
from 50–100 ng of poly(A)+ mRNA from a human cell line (a) before
and (b) after treatment with 17-allylamino-17-demethoxygeldanamycin
(17-AAG). Hybridisation signals were detected by phosphorimaging
and a pseudo-coloured intensity output is shown in (c). Red is
expression increased by 17-AAG treatment; green, expression
decreased by 17-AAG treatment. Figure provided by Paul Clarke.
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to Cy3- and Cy5-labelled probes are usually monitored by
commercial readers that typically use laser confocal fluo-
rescent scanning or computer-controlled digital camera
systems (CCD). The highly regular arrangement of probes
in an array facilitates extraction of information by digital
imaging processing software packages. The software
packages usually have facilities for semi-automatic identifi-
cation of probe spots and several methods for processing
and presenting the raw data on the fluorescence intensities
obtained for each individual pixel within the spot. Informa-
tion on some of the currently available systems is provided
in [1] and is available at the websites listed in Table 1.
Selection of the gene set
When analysing expression profiles, it is important to select
an appropriate gene set. Ideally, all the genes in the genome
would be present in the array, but this is currently only pos-
sible for certain lower organisms such as the yeast Saccha-
romyces cerevisiae. Only around 7,000 human genes have
been identified by conventional approaches to gene discov-
ery, compared to the predicted total of 50,000 genes. An
alternative strategy for gene discovery involves the large-
scale sequencing of expressed sequence tags (ESTs) ran-
domly selected from cDNA libraries prepared from many
different human tissues and cell lines. The IMAGE consor-
tium, the Cancer Genome Anatomy Project (CGAP) and
the Institute of Genomic Research (TIGR) have each made
major contributions to this sequencing project.
Table 1
Microarray Worldwide Web links
Genes and ESTs
IMAGE consortium http://www-bio.llnl.gov/bbrp/image/image.html
Cancer Genome Anatomy Project (CGAP) http://www.ncbi.nlm.nih.gov/CGAP
CGAP EST database http://ncbi.nlm.nih.gov/dbEST/index.html
UniGene resources http://www.ncbi.nlm.nih.gov/UniGene
Purchasing UniGene clones http://image.llnl.gov/image/html/idistributors.shtml
ESTs identified by the Institute of Genomic Research (TIGR) http://www.tigr.org
Research Genetics http://www.resgen.com/index.php3
Incyte http://www.incyte.com
Ensembl resources http://www.ensembl.org
Microarray laboratories
Ed Southern http://www.bioch.ox.ac.uk/rgroups/rgroupslist.asp
Pat Brown laboratory http://cmgm.stanford.edu/pbrown/index.html
National Human Genome Research Institute (NHGRI) http://www.nhgri.nih.gov/DIR/LCG/15K/HTML
Vivian Cheung Laboratory http://w95vcl.neuro.chop.edu/vcheung
Albert Einstein College of Medicine http://sequence:aecom.yu.edu/bioinf/funcgenomic.html
Institute of Cancer Research http://wyvis.icr.ac.uk
Company links
Affymetrix http://affymetrix.com
Chroma http://chroma.mbt.washington.edu/hood-www/
Incyte http://www.incyte.com
Molecular Dynamics http://www.mdyn.com
Genometrix http://www.genometrix.com
Hyseq http://www.hyseq.com
BioRobotics http://www.biorobotics.co.uk
General Scanning http://www.genescan.com
Gene Logic http://www.genelogic.com
Bioinformatics links
Stanford Link Page http://genome-www4.Stanford.EDU/MicroArray/SMD/restech.html
Figure 2
Construction of Affymetrix arrays. Modified from [17]. P is the
protecting group.
A program called UniGene has been used to identify clus-
ters of overlapping EST contigs (continuous runs of
sequence) that represent a unique gene set, and represen-
tatives of each cluster are commercially available as the
UniGene set from selected companies including Genomic
Solutions and Research Genetics. Genomic Solutions has
also been able to extend its set via access to information
from Incyte, a commercial organisation that has sequenced
more than 3 million ESTs, producing a sequence-verified
set of over 10,000 genes. The program Ensembl, which
continuously scans the nearly completed human genome
sequences obtained as part of the Human Genome Project
and combines information from EST databases and predic-
tion algorithms, has already identified more than 35,000
putative genes. The website addresses providing detailed
information on EST sequences, the UniGene sets and
Ensembl predictions are listed in Table 1.
Genetic gains and losses
Variation in gene dosage through either amplification or
deletion of genomic regions is a frequent feature of human
cancer. Amplification of genomic regions is believed to
result in the overexpression of genes that drive tumour
development and/or are involved in conferring drug resis-
tance. In breast cancer, an amplification event at 17q
results in overexpression of the CERBB2 gene; amplifica-
tion at 12q13–15 can cause overexpression of the MDM2
and CDK4 genes; and several different genes including
AIB1, ZNF217 and BTAK have been proposed to corre-
spond to the gene driving an amplification event found at
20q13 [20–22]. Amplification events in breast cancer
have attracted particular attention because they can often
be used as clinical markers of tumour behaviour [23–25],
as in studies on ERBB2 amplification.
The technique of comparative genomic hybridisation
(CGH) was developed to monitor genome-wide variations
in DNA copy number. In this technique, differentially
labelled test DNAs from a tumour and from normal tissue
are co-hybridised to metaphase chromosomes [26]. The
relative levels of hybridisation of test and control probes
can indicate loss, gain or amplification of specific genomic
regions. The resolution of this technique is poor, probably
in the region of 10–20 megabases (Mb). The use of
microarrays of mapped cDNAs or genomic clones (for
example, bacterial artificial chromosomes [BACs]) instead
of metaphase chromosomes as the probe for hybridisation
offers the prospect of dramatically increasing the resolu-
tion of the CGH studies. In such investigations, the resolu-
tion would simply be determined by the genomic map
distance between arrayed DNA segments.
The utility of this approach was first shown by Pinkel et al
[27] who carried out CGH studies on arrayed BAC clones
from chromosomes 20 and X, with the chromosome 20
clones mapping at an average interval of 3 Mb along the
entire chromosome. Comparison of cells containing differ-
ent copy numbers of DNA initially demonstrated that fluo-
rescence ratios were proportional to copy number.
Application of this technique to breast cancer yielded a
high-resolution map of amplification at 20q13.2 in several
cell lines, revealing the presence of three distinct regions of
amplification. Previous work had discounted two of these
regions as loci containing important cancer genes.
However, the microarray studies revealed that both could
be highly amplified and should therefore be reconsidered
for their potential involvement in breast cancer develop-
ment. In addition, the CGH analyses detected a short
region of deletion. This deletion, which was in the same
position as a recurrent deletion found in acute myeloid
leukaemia, was confirmed by interphase fluorescence in
situ hybridisation (FISH) studies. On the basis of this analy-
sis, Pinkel et al concluded that, within the 20q region, mul-
tiple regions may be altered during tumour development
and the complexity of amplification events in breast cancer
may be significantly greater than previously recognised.
Pollack et al [28] used arrayed cDNAs in a genome-wide
analysis of DNA copy number changes. The rationale of
this approach is that if the set of arrayed cDNAs is suffi-
ciently large it should contain representatives of all regions
of the genome. The ability of this technique to detect varia-
tions in copy number was again initially confirmed in CGH
studies using DNA from cell lines containing different
numbers of X chromosomes. The procedure was then
used to map chromosomal genes in the BT474 breast
carcinoma cell line. The fluorescence ratios of hybridisa-
tion to BT474 genomic DNA and normal female genomic
DNA was determined for 3,360 cDNAs whose chromoso-
mal positions had been located onto radiation hybrid
maps. An example of such a result is shown in Figure 3.
These analyses not only confirmed the presence of known
amplification events on chromosomes 17q and 20q, but
also detected many previously uncharacterised over-repre-
sentations on 1q, 8q, 11q and 15q, as well as deletions
on chromosomes 3p, 6q, 9p, 10q and Xq. The usefulness
of this technique to identify novel amplified genes was
demonstrated when it was applied to the analysis of the
NGP neuroblastoma cell line, leading to the discovery of
the amplification of the zinc-finger gene ZNF133 on chro-
mosome arm 20p [29].
Tumour classification
Microarray technology provides a method for monitoring
the RNA expression levels of many thousands of genes
simultaneously in primary tumours and cell lines. In princi-
ple, data from such studies could revolutionise cancer
diagnosis. The rationale behind this proposition is that the
overall behaviour of a cancer must be determined by the
expression of the genes within it. It should, therefore, be
possible to identify sets of genes whose expression or lack
of expression defines each individual property of a tumour,
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including its precise diagnosis and clinical behaviour. The
potential of this approach was demonstrated by Golub et
al [30] who determined the RNA expression profiles of a
series of acute myeloid leukaemias (AML) and acute lym-
phoblastic leukaemias (ALL). A class discovery program
automatically identified the distinction between these
leukaemia groups without prior knowledge of the diagno-
sis. Using this data set, the program was then able to clas-
sify new leukaemia cases. Alizadeh et al [31] extended this
approach to the analysis of diffuse large B-cell lymphoma
(DLBCL), the most common subtype of Hodgkin’s lym-
phoma. Analysis of the microarray expression profiles led to
the definition of two molecularly distinct categories of
DLBCL. One subtype, which had a statistically significant
better overall survival, had a gene expression profile char-
acteristic of germinal B cells. The second subtype, which
had poor prognosis, expressed genes normally induced fol-
lowing in vitro activation of peripheral blood B cells. This
study showed that microarray technology has the potential
for identifying previously uncharacterised and clinically sig-
nificant tumour subgroups. Interestingly, these analyses
also highlighted the potential limitations of the microarray
approach, as the two new DLBCL groups were not
monomorphic. For example, within the group showing
overall favourable prognosis, five patients in fact died within
two years of diagnosis, whereas three patients from the
poor prognosis group were alive after five years. The
authors proposed that more extensive microarray analyses
might reveal additional markers that would improve the pre-
dictive value of microarray profiling.
Ross et al [32] used cDNA microarrays to determine the
expression of 8,000 genes within the 60 cell lines used in
the National Cancer Institute screen for anticancer drugs
(the NCI60 cell lines). When hierarchical clustering analy-
sis was performed, cells of the same tissue origin usually
grouped together. Clustering was observed for groups of
cell lines derived from leukaemia, melanoma, the central
nervous system, colon, kidney and ovarian tissue
(Figure 4). However, lines derived from breast tissue were
located in multiple distinct branches, suggesting a hetero-
geneous pattern of gene expression. More specifically, the
profile obtained for two related breast carcinoma cell lines,
MDA-MB435 and MDA-N, that were derived indepen-
dently from the same patient, was similar to that from
melanoma cell lines (Figure 4). This suggested either that
some breast cancers may have expression profiles exhibit-
ing neuroendocrine features or that the cell lines are actu-
ally derived from a melanoma.
A potential problem with the application of microarray tech-
nology to primary human tumour specimens is that the spec-
imens may represent mixtures of cell types. The presence of
variable levels of normal cells, supporting stroma, blood
vessels and lymphocytes in samples could mask expression
patterns attributable to cancer cells. To investigate this
issue, Ross et al [32] determined the microarray profiles of
specimens of primary breast carcinoma. The samples
expressed sets of genes in common with two breast-derived
cell lines MCF-7 and T47D, stromal cells, and cells of
haematopoietic lineage. This is consistent with the presence
of stromal tissue and lymphocyte infiltration within the
primary cancer specimens. Such a study indicates that, for
optimal analysis of primary breast tumours, it may be neces-
sary to microdissect tumour specimens to separate popula-
tions enriched in cancer cells and/or to electronically remove
signals believed to result from contamination with normal
cells. Despite these potential pitfalls, microarray profiling has
been applied to the gross analysis of primary cancer speci-
mens. For example, using an Affymetrix GeneChip contain-
ing 6,500 human genes, Alon et al [33] determined the
expression profiles for a series of 40 colon adenocarcino-
mas and 22 normal colon tissue samples. Clustering analy-
sis demonstrated that cancerous and non-cancerous
specimens could be readily distinguished.
Sgroi et al [34] demonstrated that laser capture microdis-
section (LCM) can be used to obtain high-quality microar-
ray profiles from primary breast carcinomas. LCM was
used to isolate purified populations of normal breast
epithelial cells, invasive cells and metastatic cells from a
single patient. Labelled cDNA targets were then hybridised
to an array of 8,084 cDNAs. These studies identified genes
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Figure 3
Comparative genomic hybridisation (CGH) on human cDNA clones
microarrayed onto a glass slide. The slide was hybridised
simultaneously to normal DNA (green) and DNA from a breast cancer
cell line (red). (a) Complete array of 6,000 cDNAs; (b) magnified
region of the array showing the CERBB2 gene (arrow). The red colour
of this array point indicates that the CERBB2 gene is amplified. Figure
provided by Jeremy Clark.
(a) (b)
that were differentially expressed in normal, invasive and
metastatic cells, and the differences in expression were
verified by real-time quantitative polymerase chain reaction
(PCR) and by immunohistochemistry. Genes found overex-
pressed in invasive and metastatic disease compared to
normal tissue included the breast cancer susceptibility
gene BRCA1 and genes for apolipoprotein D, annexin I
and the chemokine RANTES.
Thirteen grade II–III grossly dissected infiltrating breast
ductal carcinoma specimens were also examined as part of
this study. Several clusters of genes showing altered
expression were detected. A cluster of genes involved in
cellular proliferation was highly expressed in a subset of
tumours and a correlation was observed between the level
of expression of these genes as determined in the microar-
ray studies and the number of cells positive for the Ki-67
proliferation-associated antigen. The patterns of expression
were also consistent with the presence of lymphocytes and
stromal cells in the primary tumour specimens. The inter-
feron-regulated gene cluster identified in studies of cultured
mammary epithelial cells was highly expressed in some
tumours, moderately in others, and was silent in others.
Perou et al [35] obtained microarray portraits of a set of
65 surgical specimens of human breast tumours from 42
individuals. There was considerable variation in the pattern
of gene expression among the tumours. This variation
could be partly due to changes in the levels of certain cell
types within the tumours, such as endothelial cells,
stromal cells, adipose-enriched normal breast cells, B and
T lymphocytes and macrophages. Once genes character-
istic of these cell types had been excluded, the authors
selected a subset of 496 genes, called the ‘intrinsic’ gene
set, that still showed considerable variation in expression
levels between different tumours. When variations in level
of expression within the genes were used to order the
tissue samples, a striking division of the tumours into
oestrogen receptor (ER)-positive and ER-negative cate-
gories occurred. Interestingly, the ER-positive group was
characterised by the expression of many genes specific to
breast luminal cells. The ER-negative tumours could be
further divided into several subgroups. A subgroup of six
tumours had an expression pattern characteristic of breast
basal (myoepithelial) cells, whereas another subgroup was
partially characterised by high expression levels of genes
associated with overexpression of the ERBB2 oncogene.
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Figure 4
(a) (b)
Classification of tumours on the basis of microarray expression profiles.
(a) Dendrogram showing hierarchical clustering based on expression
data from a set of 1,164 cDNAs measured across 64 cell lines. (b) A
coloured representation of the data rows (genes) and columns (cell
lines) in cluster order. The colour in each cell of the table represents the
mean-adjusted expression level of the gene, with green showing
underexpression and red indicating overexpression according to the
chart in (b). The labels 3a–3d refer to clusters of genes for leukaemias
(3a), epithelial tumours (3b), melanoma (3c) and mesenchymal tumours
(3d). Published with permission from Nature Genetics [32].
On the basis of these results the authors suggested that
we are far from a complete understanding of the diversity
of human breast tumours.
Drug discovery and development
Microarray technology can, in principle, provide many
types of information to help drug discovery and develop-
ment. In their simplest application, microarrays can be
used to screen for changes in gene expression following
exposure of tumour cells to drugs either in culture or in
patients following treatment. Studies of this type may
provide information on the precise mechanism of action of
the drug or could lead to the identification of early markers
of drug response. For predicting the longer-term clinical
response to drug treatment, microarray information could
also yield information about possible side effects, and
identify markers that, in a clinical context, could be used to
predict possible adverse events. This technology can also
provide information for identifying and validating new ther-
apeutic targets (reviewed in [36]).
Scherf et al [37] used microarrays to determine the
expression profiles of 9,703 genes in the NCI60 cell lines.
To dissect the mechanisms of drug action, they combined
the database of gene expression data obtained in this
study with molecular pharmacology data that had been
obtained using the same cell lines. They constructed a
dendrogram of relationships between a set of 188 drugs
based only on the activity pattern of the drugs against the
NCI60 cell lines. Five large drug clusters were obtained,
corresponding to different mechanisms of drug action:
DNA and DNA/RNA antimetabolites; tubulin inhibitors;
DNA-damaging agents; topoisomerase I (Top1) inhibitors;
and topoisomerase 2 (Top2) inhibitors. When data from
gene expression and drug activity patterns were used
together to construct the dendrogram, however, many of
the clusters were altered. In some cases, the changes
were not clearly related to known mechanic or metabolic
characteristics of the drug, suggesting the existence of
hitherto unsuspected biological relationships between
drugs that remain to be unmasked. In other cases, the
changes could be interpreted on the basis of our current
knowledge of the drug. For example, for the topoiso-
merase inhibitors, mechanistic distinctions between indi-
vidual drugs were revealed: Top1 inhibitors that did not
required activation clustered together, whereas prodrugs
formed a distinct group. In addition, a subgroup of the
Top2 inhibitors, including mitoxanthrone and oxanthrazole,
clustered close to porfiromycin and mitomycin, suggesting
that the ability to induce double-stranded DNA breaks may
be a common feature of these drugs.
A good example of how the NCI60 data set can be used to
generate new clinical hypotheses is provided by the analy-
ses of the effects of 5-fluorouracil (5-FU), which is used to
treat both colorectal and breast cancer. The NCI60
microarray data unveiled a very strong negative correlation
between the level of dihydropyrimidine dehydrogenase
(DPYD) mRNA and the potency of 5-FU, with most of the
lines deficient in DPYD showing high levels of sensitivity to
5-FU [37]. Indeed, DPYD catalyses the rate-limiting step in
the catabolism of uracil, thymidine and 5-FU, so tumours
with high levels of this enzyme are expected to show resis-
tance to 5-FU. These observations suggested that DPYD
should be investigated further as a possible marker of
response of breast and other cancers to 5-FU.
Marton et al [38] used a yeast model system to validate
drug targets and identify secondary drug targets. The
method was applied to FK506 and cyclosporin A (CsA),
drugs that inhibit calcineurin activity in both mammalian
and yeast cells and are used clinically as immunosuppres-
sants. Calcineurin is a highly conserved calcium- and
calmodulin-activated serine/threonine protein phos-
phatase that is required in yeast for intracellular ion home-
ostasis, regulation of the onset of mitosis, and response to
mating pheromone. Treatment of wild-type S. cerevisiae
by FK506 or CsA resulted in a signature pattern in which
the levels of expression of a small group of genes (36 for
FK5076) were altered more than twofold. A very similar
signature pattern was found in an untreated yeast mutant
that had deletions of the genes encoding calcineurin cat-
alytic subunits, demonstrating the equivalence of removal
of calcineurin function by either drug action or genetic
deletion. To assist target validation, a second or ‘decoder’
step was used in which the yeast strain mutated in the
proposed target gene is treated with the drug. If the
mutated gene encodes a protein involved in the pathway
targeted by the drug, the microarray signature pattern
should not be altered. Application of this ‘decoder’ strat-
egy to FK506 and CsA confirmed that their characteristic
signature pattern was not observed in the strain with the
mutated calcineurin genes when exposed to these drugs.
To investigate secondary drug effects, wild-type yeast
strains were exposed to higher doses of FK506 and CsA,
leading to much more complex alterations in microarray
expression profiles. Significantly, many of the new alter-
ations in expression were also observed when strains har-
boured mutations in calcineurin genes, indicating that they
resulted from secondary drug effects in calcineurin-inde-
pendent pathways. Further investigation revealed that
FK506 may have several other targets, including the drug
efflux pump PD45 and a pathway involving the transcrip-
tional activator Gcn.
This approach has been extended by producing a com-
pendium of profiles corresponding to 300 yeast mutations
and chemical treatments. Comparisons with this com-
pendium can then be used to investigate the mechanism
of drug action [39]. For example, treatment of yeast with
the anaesthetic drug dyclonine caused profiles that
Breast Cancer Research    Vol 3 No 3 Cooper
resemble those resulting from perturbation of the ergos-
terol pathway. Biochemical analysis subsequently indi-
cated that the sterol C-8 isomerase Erg2p within this
pathway may represent the drug target in yeast. The
human homologue of Erg2p is known as the sigma recep-
tor, a neurosteroid-intracting protein that regulates potas-
sium conductance and binds to known neuroactive drugs.
It was therefore proposed that the anaesthetic properties
of dyclonine in humans may be mediated by its binding to
the sigma receptor.
A yeast model system has been used to investigate the
mechanism of action of fluaropiridol and a purvalanol ana-
logue called compound 52, which inhibit human and S.
cerevisiae cyclin-dependent kinases (CDKs) [40]. Sixty-
two transcripts were identified whose levels changed more
than twofold in wild-type yeast in response to treatment
with either drug. They included groups of genes involved in
cell-cycle progression (CLB1, CLB2, HTA2, HTB2 and
EGT2) and phosphate metabolism (PHO80, PHO81,
PHO84, PHO5, CTT2, HSP12 and UBI4). These two
groups of alterations were entirely consistent with the
demonstrated ability of compound 52 to inhibit both the
cell-cycle-regulating kinase Cdc28p and the Pho85p
kinase, which is involved in phosphate metabolism.
Using a filter microarray of 4,132 genes and 32P-labelled
targets, Clarke et al [41] investigated alterations in gene
expression pattern in human colon cancer cell lines follow-
ing inhibition of signal transduction by 17-allylamino-17-
demethoxygelanamycin, an inhibitor of the molecular
chaperone, heat-shock protein 90 (HSP90). Biochemical
studies demonstrated that treatment of each of four colon
cancer cell lines resulted in depletion of RAF1 and AKT
proteins and inhibited signal transduction. The array
studies revealed that the genes for HSP70, HSP90B and
caveolin were upregulated, whereas the genes for keratins
8 and 18 were consistently downregulated. Interestingly,
expression of genes for the protein clients of HSP90 was
not affected by drug treatment. The authors suggest that
these genes could be used as possible molecular markers
of drug action in clinical trials.
Mutation detection
As the Human Genome Project nears completion and
alterations in more genes become implicated in human
pathology, there will be a growing demand for techniques
allowing high-throughput resequencing of genomic DNA.
In the breast cancer field, there is already a requirement
for large-scale population-based detection of inherited
mutations within genes such as BRCA1, BRCA2, P53
and CHK2, which predispose towards the development of
this disease. Such studies could provide information on
the prevalence of particular classes of mutations and,
through the collection of epidemiological data, shed some
light on the possible role of aetiological agents in cancer
development. Large-scale screening studies on new
genes found to be somatically mutated in breast cancer
might lead to the identification of molecular diagnostic
markers and, through analysis of mutational spectrum,
provide clues to the possible role of chemical exposure in
breast cancer development.
Affymetrix arrays for comparative sequencing
Several microarray-based strategies have been developed
to facilitate large-scale comparative sequencing. Hacia et
al [42,43] have described a ‘gain-of-hybridisation signal’
approach to identification, in which the arrays contain
large sets of oligonucleotides complementary to all possi-
ble sequence changes under investigation. Hybridisations
are performed under conditions in which fluorescently
tagged target DNA only binds to wild-type and mutant
oligonucleotides that are exactly complementary to its
sequence, leading to a gain-of-hybridisation signal at
selected oligonucleotide positions. The Affymetrix array for
identifying mutations in the BRCA1 gene contains over
96,000 dimers corresponding to wild-type sequences and
all possible single-base substitutes, single-base insertions
and 1–5 base pair (bp) deletions. To detect substitution
mutations, the array contains four oligonucleotides for
each position in the BRCA1 sequence. One oligonu-
cleotide is precisely complementary to the wild-type
sequence, whereas the remaining three are complemen-
tary to the three possible substitution mutations at that
position. To maximise the discrimination of hybridisation of
target sequences to the oligonucleotides, the base being
interrogated is positioned in the centre of the oligonu-
cleotide. Hybridisation to the array is then performed using
a two-colour system to provide a direct comparison
between wild-type sequence and the test sample poten-
tially containing a mutant sequence. The strategy is shown
in Figure 5a. Disappointingly, only four of the fourteen
BRCA1 mutations examined could be detected by this
method. An example of the results obtained by Hacia et al
[42] is shown in Figure 6.
Hacia et al [42] also utilised a ‘loss-of-signal’ analysis to
glean additional information from the BRCA1 Affymetrix
array. In this approach, changes in the signal ratio
between test and wild-type target samples are monitored
(Figure 5b). Homozygous loss (complete loss of wild-type
sequence) in the test sample should result in total removal
of the hybridisation signal, whereas heterozygous muta-
tions should cause a 50% reduction in signal intensity.
Whereas this strategy does not, unfortunately, provide
information on the nature of the mutations, the sensitivity
of detection is improved, as 14 of the 15 BRCA1 muta-
tions screened were detected.
Affymetrix arrays have now been used to interrogate
BRCA1 and BRCA2 and gene sequences from human
mitochondria, P53 and the human immunodeficiency
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virus (HIV) [3,42–47]. For example, analysis of germline
P53 mutations in 42 breast cancer families using these
arrays identified three families with a G to C base
change at nucleotide 13,964 [45]. A significant chal-
lenge for this technology is to develop assay conditions
where an even hybridisation of targets to attached
oligonucleotides is achieved, irrespective of the base
composition of the sequence (the GC:AT ratio). To
address this issue, Hacia et al [19] incorporated modi-
fied bases into target sequences and found that targets
containing 5-methyluridine gave a more even signal and
retained hybridisation specificity.
Minisequencing assay
High-density oligonucleotide chips have some potential
drawbacks, such as low sensitivity in the gain-of-hybridisa-
tion strategy and high background and problems in
achieving even hybridisations across all sequences inde-
pendently of the GC:AT composition. To overcome these
problems, alternative microarray-based sequencing strate-
gies have been developed. In the ‘minisequencing’ assay
(reviewed in [48]), target hybridisation is combined with
an enzymatic primer extension assay. Oligonucleotides are
attached to the surface by their 5′ ends, leaving free 3-OH
groups. Following hybridisation to the test DNA, the
attached oligonucleotide acts as a primer for nucleotide
incorporation at the 3-OH, using the hybridised test DNA
as a template (Figure 5c). The extension reaction contains
a mixture of four dideoxyribonucleoside triphosphates,
each tagged with a distinct fluorescent label. The pres-
ence of dideoxyribonucleotides ensures that only a single
fluorescently tagged nucleotide is added to each 3′-OH
group, so that the identity of the tagged nucleotide that
becomes covalently attached to each oligonucleotide can
be monitored by fluorescence microscopy. To scan both
strands of a sequence of length N using this approach the
array must contain 2N oligonucleotides, each with its 3′-
OH immediately preceding the base to be interrogated. It
is important to note that Affymetrix chips are not suitable
for microsequencing because the oligonucleotides are
attached to the surface through their 3′-OH ends.
Universal DNA microrarrays
A universal DNA microarray method may be used for high-
throughput detection of small groups of previously charac-
terised mutations [49–51]. In this procedure, the
PCR-amplified target gene sequences are annealed to
two oligonucleotides (called the upstream and down-
stream LDR primers) that complement immediately adja-
cent regions in the genomic DNA flanking the nucleotide
under investigation. The two annealed primers are then
subject to a ligase detection reaction (LDR) that links the
two oligonucleotides if, and only if, the correct base paring
is present at the junction (Figure 5d). The upstream allele-
specific LDR primer contains a nucleotide complementing
the mutant sequence being interrogated at its most 3′ end
and a ‘zip code’ sequence composed of a six tetramer
repeat, for example (CGTT)6, at its 5′ end. The down-
stream LDR primer contains a fluorescent tag that
becomes covalently joined to the oligonucleotide contain-
ing the zip code sequence if ligation is successful. Four
different upstream primers, each containing a unique zip
code sequence and a different base at their 3′ ends are
used to screen for substitution mutations at each
nucleotide position. After the LDR step, the unique zip
code sequences are used to direct the LDR products con-
taining the fluorescent tag to specific complementary zip
code address sequences attached covalently in an array
format to a glass microscope slide (Figure 5e). For
example, the zip code address (AACG)6 attached to the
glass surface would be used to bind the (CGTT)6 oligonu-
cleotide zip tag mentioned above. The technique is
referred to as ‘universal’ DNA microarray analysis because
the arrayed zip code addresses remain constant and their
complementary zip code tags can be attached to any set
of LDR primers. This approach can detect mutation with
extreme selectivity, even when the mutant sequence is
only present at low abundance (down to 1:200). This
technique has been successfully applied to the detection
of point mutations in KRAS and P53 in human tumours
and to the detection of small insertions and deletions in
BRCA1 and BRCA2 [49,50,52].
Determining the function of normal or
mutated genes
Gene function may be monitored by examining the pertur-
bations of gene expression after introduction of either
normal or mutated genes. Studies involving, for example,
transformation of NIH3T3 cells by the PAX-FKHR onco-
genes revealed activation of the myogenic transcription
programme involving upregulation of genes for the tran-
scription factors MyoD, myogenin, Six and Slug, as well as
many other genes involved in muscle function [53].
BRCA1 encodes a protein that has been implicated in the
cellular response to DNA damage. Affymetrix GeneChip
arrays were used to monitor altered gene expression fol-
lowing induced expression of BRCA1 in U20S osteosar-
coma cells and in MDA435 breast cancer cells [54].
BCL1 was constitutively expressed in these cells to
prevent apoptosis, which usually occurs after introduction
of BRCA1. Twenty-three genes and ESTs had increased
expression following BRCA1 induction. These included
the DNA-damage-inducible gene GADD45 (35-fold) and
the immediate early gene, early growth response 1
(EGR1) (10-fold). Repressed genes included Ki67 (12-
fold) and the gene for prothymosin-α (4-fold), which have
both previously been implicated as possible prognostic
markers in breast cancer. The induction of GADD45 was
associated with the p53-independent activation of the Jun
N-terminal kinase (JNK)/stress-activated protein kinase
(SAPK) pathway, which may be involved as a possible
pathway for BRCA1-induced apoptosis.
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An array of 6,416 genes was used to investigate the
effects of the overexpression of the proto-oncogene
CMYC in primary human fibroblastomas [55]. Following
retroviral infection with a construct expressing CMYC, 27
genes were consistently upregulated and 9 were consis-
tently downregulated [56]. The downregulation of the
extracellular matrix proteins fibronectin and collagen and
of the cytoskeletal protein tropomyosin indicated that
CMYC may have a role in modulating cell adhesion and
cell structure. Several cell-cycle genes were identified as
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Figure 5
Strategies for DNA sequencing. (a) Gain-of-hybridisation approach: an
array is hybridised to normal DNA which has the base T at the position
under interrogation or to test DNA containing a heterozygous T→G
mutation. (b) Loss-of-hybridisation approach: in this example the array
is hybridised to a mixture of normal DNA (solid bars) and DNA
containing a mutation (open bars). The mutation is detected by its
inability to hybridise at oligonucleotide positions that do hybridise to
normal control DNA sequences. (c) Minisequencing: an array
containing oligonucleotides attached at their 5′ ends is hybridised to
the target DNA and then incubated with a mixture of fluorescently
tagged dideoxynucleoside triphosphates (ddNTP*) and DNA
polymerase. Covalent attachment of the tagged ddNTP* is only
possible if it complements the target sequence. (d) Universal array
sequencing: the target sequence is hybridised to upstream LDR
primers attached to ‘zip code’ sequences (Z1, Z2, etc) and to a
downstream LDR primer containing a fluorescent tag. The two primers
are only joined if the correct base pairing is present at the junction. (e)
The ligated mixture is then hybridised to a universal array containing
sequences complementing the ‘zip codes’.
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targets, including those for cyclin D2 and the cyclin-depen-
dent kinase-binding protein CKSHS2, which were induced,
and the P21Gp1 gene, which was repressed. Identification
of the gene encoding the tumour necrosis factor receptor-
associated protein TRAP1 as a target suggested a poten-
tial link to an apoptosis-associated pathway. The results
were compared to data obtained using the same microar-
ray in experiments in which HL60 cells were induced to
undergo differentiation by exposure to phorbol ester (TPA),
a process that involves rapid downregulation of MYC
expression. Notably, 17 of the 27 genes upregulated fol-
lowing CMYC expression in human fibroblasts were down-
regulated in this experiment, providing further evidence for
the role of CMYC in their regulation.
Induction of p53 expression from a metallothionein pro-
moter in the p53-deficient colon-derived EB1 cell line
results in cell death by apoptosis within 1–4 hours.
Microarrays were used to identify 161 genes whose
expression was altered more than threefold following p53
induction [57,58]. These genes could be divided into
eight clusters with distinct expression kinetics following
p53 induction, and into several distinct functional groups,
such as genes involved in cell regulation (P21, GADD45
and GOS8), apoptosis (FAS, KILLER), oxidative stress
(PIG3, genes for neutrophil NADPH oxidase and superox-
ide dismutase 3), cell structure (genes for collagen and
NRP/B nuclear matrix protein), signal transduction (ECK,
P2XM, EPR1, ACK, HSR1, ARL2, C/EBPα, TGF-α) and
oncogenes (genes for endothelin 2 and thrombospondin).
Response to radiation
Amundson et al [59] identified 48 sequences whose
expression was changed when the ML-1 human myeloid
cell line, which contains wild-type p53, was treated with
ionizing radiation. Many of these transcripts were not
known to be induced by radiation exposure. Analysis of a
subset of these genes in a series of 12 cell lines, including
the MCF7 and T47D breast cancer cell lines, following
exposure to ionizing radiation, UV radiation or methyl-
methanesulphonate (MMS) treatment revealed a heteroge-
neous response pattern with the exception that expression
of the ATF3 gene was consistently upregulated following
UV or MMS treatment. ATF belongs to the ATF/CREB
family, whose members can homodimerise to repress tran-
scription from promoters containing ATF-binding sites.
ATF3 can be induced following stresses such as exposure
to carbon tetrachloride (CCl4), alcohol intoxication and
wounding, and may have a key role in modulating cellular
response to radiation and chemical exposure. The studies
also provided evidence that a second gene, FRA1, was
involved in the p53-associated response to radiation treat-
ment. Following γ-irradiation, expression of this gene was
upregulated in MCF7 breast cancer cells that contain
wild-type p53, but no response was observed in
MCF7/E6 cell lines, which lack wild-type p53 function.
Figure 6
The use of an Affymetrix DNA microarray to sequence the BRCA1
gene. The array is hybridised with a mixture of normal DNA (green) and
test DNA from a carrier of the BRCA1 mutation (red). Equal
hybridisation to the two probes gives yellow. (a) Composite image of
hybridisation to normal control and test DNA. (b) Magnification of the
region surrounding the 2,457 C→T mutation. (c) Close-up of the
probe sets surrounding the 2,457 C→T mutation. The bright red signal
online indicates the presence of the mutation. Published with
permission from Nature Genetics [42].
In a more extensive investigation of the mechanism of radi-
ation-induced apoptosis using a 11,000-gene microarray,
Voehringer et al [60] compared expression profiles in
apoptosis-sensitive and apoptosis-resistant mouse B-cell
lymphomas, both before and after exposure to 5 Gy of
γ-irradiation. In these studies, 184 genes were uniquely
induced following irradiation in the apoptosis-resistant
line, and 617 were uniquely induced in the apoptosis-sen-
sitive line. One interesting cluster of genes induced in the
apoptosis-sensitive cells disrupts normal mitochondrial
function. These included Vdac-1, which has been recog-
nised to be part of the permeability transition (PT) pore,
which has a central role in controlling apoptosis, and
Ucp-2, which is believed to be involved in uncoupling
electron transfer from oxidative phosphorylation. As Ucp-2
expression peaked before apoptosis-associated mitochon-
drial changes, it was proposed that Ucp-2 may have a role
in regulating apoptosis. These studies also identified a
pathway involving the expression of a family of Fabp (fatty-
acid-binding protein) genes that may be important in pre-
venting apoptosis in the resistant line. The upregulation of
FABP proteins is significant, because they bind fatty acids
such as retinoic acids, which can function as signals for
differentiation as well as for apoptosis. The authors
propose that FABPs may have a specific role in sequester-
ing fatty acids that act as apoptotic signals. An alternative
explanation is that they may act as scavengers that bind to
the oxidised fatty acids generated during oxidative stress,
thus terminating a cascade of lipid peroxidation which may
represent an early step in commitment to apoptosis.
Subcellular fractionation
Subcellular fractionation may be combined with microarray
technology to investigate gene function. This approach
has been used to identify eukaryotic mRNAs that are
translated in the absence of the cap-binding complex
eIF4F [61]. Most eukaryotic mRNA needs a functional
cap-binding complex for efficient translational initiation.
However, a few cellular RNAs and transcripts produced
from hepatitis C virus and picornaviruses can function
even in the presence of low levels of eIF4F. Polyribosomes
were first prepared from human cells depleted for eIF4F.
Analysis of the polyribosome-associated mRNA on
microarrays showed that approximately 200 of the 7,000
microarrayed genes remained associated with the polyri-
bosome, including the MYC and PIM1 proto-oncogenes
and genes for immediate early transcription factors,
kinases and phosphatases.
Subcellular fractionation has also been used by Diehn et
al [62] to identify secreted and membrane-associated
gene products. mRNA species bound to membrane-asso-
ciated polysomes were first separated from other cytosolic
mRNA by sedimentation. The different fractions were then
used to prepare labelled cDNA probes that were
hybridised to microarrays. Based on these analyses, 275
human gene and 285 yeast genes were identified that
potentially encoded previously unrecognised secreted or
membrane-associated proteins [63].
Gene deletion
Gene deletion or inactivation, for example by the produc-
tion of knockout mice or mutations, may also be combined
with microarrays to investigate gene function. An elegant
demonstration of the power of this approach was provided
by Hughes et al [39], who used a yeast microarray to
compile a database of expression profiles for 300 muta-
tions and chemical treatments. Analysis of the 300 profiles
present in the compendium identified groups of co-regu-
lated transcripts as well as groups of experiments with
similar profiles, and it appeared that different mutations
affecting the same cellular process in general displayed
related profiles. To determine the function of novel yeast
genes, the profile caused by deletion of the uncharac-
terised gene was then compared to the compendium.
Using this approach, this group identified and experimen-
tally verified the involvement of new genes in cell wall
function, mitochondrial respiration and protein synthesis.
Treatment by agents that induce growth and
differentiation
A very simple experimental design involves the analysis of
alteration of gene expression profile following exposure of
cells to growth factors or agents that induce differentiation
or apoptosis. Perou et al [64] utilised a glass-based array
system to analyse the gene expression patterns of
mammary epithelial cells grown in culture and subjected to
a variety of experimental perturbations. Epithelial cells
were treated with transforming growth factor-β1 (TGF-β1),
interferon-α (IFN-α) or IFN-γ, and were also subjected to
withdrawal of epidermal growth factor (EGF). The effects
of senescence and growth in Matrigel were also exam-
ined. Analysis of the data by hierarchical clustering
revealed that reduction in cell proliferation rate, which
occurred with several of the treatment protocols, was
associated with alteration in expression levels of a specific
set of genes involved in cell-cycle progression, including
MCM2, MCM3, MCM6 (cyclin B), and Ki-67. When cul-
tures became confluent or underwent senescence, many
interferon-regulated genes were consistently induced, for
example those for (2′-5′) oligoadenylate synthetase E,
interferon-induced 17 kDa protein and Stat1. Induction of
transcription from this gene set is modulated by the
JAK/STAT signalling pathway, and Perou et al suggest
that reaching confluence and undergoing senescence
both result in activation of this pathway.
Particular attention has been directed to the analysis of
leukaemias and T- and B-cell responses. For example,
Rusiniak et al [65] examined the effects of retinoic acid
(RA) on leukaemia cells engineered to contain a fusion of
the retinoic acid receptor-α gene (PML-RARα constructs),
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the gene fusion that characterises acute promyelocytic
leukaemia. They identified B94, originally isolated as a
gene inducible by tumour necrosis factor-α (TNF-α) in
endothelial cells, as a gene induced by RA exposure.
Expression arrays have been used to investigate the
mechanism of T-cell and B-cell stimulation [66–68].
Teague et al [67] showed that T-cell activation was asso-
ciated with considerable changes in expression profile
compared to resting T cells and, as expected, many genes
associated with cell division were activated. Rogge et al
[68] compared the gene expression profiles in T helper
type1 (Th1) and T helper type 2 (Th2) cells in an attempt
to unravel the genetic programme that controls the func-
tional properties of these cells. This approach identified
15 differentially expressed genes encoding proteins
involved in transcriptional regulation, apoptosis, proteoly-
sis and cell adhesion and migration.
Iyer et al [69] examined the response of human fibroblasts
to serum treatment using a 8,600 gene array. They found
that the altered genes could be grouped on the basis of
their temporary pattern of expression. For example, genes
such as P27, KIP1, P57, KIP2 and P18 were expressed
in quiescent fibroblasts but downregulated following
fibroblast stimulation. One of the most striking features
was the altered expression of many genes known to be
involved in the physiology of wound healing, including
genes involved in remodelling blood clots, promoting
chemotaxis and activating neutrophils and T and B cells,
promoting angiogenesis and promoting the migration and
proliferation of fibroblasts and keratinocytes. Iyer et al pro-
posed that the role of fibroblasts in the response to
wounding is greater and more complex than had previ-
ously been appreciated.
Extracellular interaction of plasma clotting factor VIIa
(FVIIa) with tissue factor (TF) on the cell surface results in
intracellular signalling, but it is currently unclear which of
these signals initiates blood coagulation. Using a microar-
ray approach, Pendurthi et al [70] examined changes in
the transcriptional programme in human fibroblasts in
response to treatment with FVIIa and noted that the genes
encoding the extracellular matrix signalling protein CYR61
and connective tissue growth factor (CTGF) were upregu-
lated in a time and dose-dependent manner. Other studies
have looked at the response of HT1080 fibrosarcoma
cells to interferon treatment [71], of HL60 cells to stimula-
tion of the cannabinoid receptor [72] and of prostate
cancer cells to androgen treatment [73].
Arrays were used to investigate the effect of inhibiting DNA
methyltransferase by 5-aza-2′-deoxycytidine (5AC) in HT29
colon adenocarcinoma cells [74]. The studies revealed that
10 of 19 genes induced by 5AC were previously identified
interferon-response genes. Whereas the expression levels
of the interferon genes themselves remained unaltered,
biochemical studies show that STAT transcription factors
and interferon signalling were upregulated. As interferons
are growth inhibitors, this observation may explain the
growth inhibition observed following 5AC treatment.
Tumour growth and progression
Several distinct approaches have been used to examine
tumour growth and progression. Hilsenbeck et al [75] used
a xenograft model system to investigate changes in gene
expression during the development of acquired tamoxifen
resistance in the human MCF-7 breast carcinoma cell line.
MCF-7 cells were injected into the mammary fat pads of
athymic mice that had been supplemented with an oestro-
gen pellet to allow the tumour cells to grow. When the
pellet was removed and the animals treated with tamoxifen,
the tumours shrank and remained stable for several months
before developing resistance to tamoxifen and resuming
growth. Expression patterns were determined for the origi-
nal oestrogen-stimulated tumours (OS) before tamoxifen
treatment, for the tamoxifen-sensitive (TS) tumours during
tamoxifen treatment but before acquired resistance, and for
the tamoxifen-resistant (TR) tumours following growth
resumption. Two of the genes, ERK2 and HSF1, whose
expression altered during the transition from OS to TR,
were selected by western blot analyses. The western blot
data agreed with the array data: HSF1 protein, which is
involved in the cellular response to stress was upregulated
in TS cells compared to OS cells and downregulated in TR
cells; expression of the kinase gene ERK2 increased in the
TS tumours relative to OS tumours.
To study the effect of infection of keratinocytes by human
papilloma virus type 31, Chang and Laimins [76] used an
array containing 7,075 genes and ESTs. They identified
178 upregulated genes and 150 downregulated genes.
Although no specific pattern of alteration was identified,
the authors highlighted the fact that Stat1, a transcription
activator with a role in mediating the response to interferon,
was repressed. Bubendorf et al [77] used microarrays to
identify differentially expressed genes in hormone-refrac-
tory human prostate cancer. Differential expression
between hormone-refractory CWR22R prostate cancer
xenografts and xenografts of the parental hormone-sensi-
tive CWR22 strain was examined using a 588 cDNA Clon-
tech filter microarray. These analyses identified 10
overexpressed genes. They included the genes for insulin-
like growth factor binding protein 2 (IGFBP2), the insulin
receptor, insulin-like growth factor 3 (IGF-3) and HSP27,
as well as 14 underexpressed genes. Tissue arrays were
then used to analyse the expression of IGFBP2 and
HSP27 in 238 primary human prostate cancers. A strong
association between increased IGFBP2 and HSP27
expression and progression to hormone-refractory disease
was observed. For example, IGFBP2 was expressed in
100% of human refractory clinical tumours, in 36% of
primary tumours and in no benign tumours.
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The same Clontech microarray was used to identify genes
that had altered expression in prostate cancer compared
to normal prostate tissue [78]. The filter was indepen-
dently hybridised to 32P-labelled targets prepared from
three separate prostate tumours and from normal tissue.
Sixteen genes were found to be altered in at least two of
the three tumours. With the exception of the gene for glu-
tathione-S-transferase 1, however, reverse transcription-
polymerase chain reaction (RT-PCR) studies could not
confirm differential expression. Expression profiles were
also collected for LNCaP cells grown in the presence and
absence of the androgen analogue R1881. Androgen
treatment appeared to cause the upregulation of several
genes including HSP27, DBI (diazepam-binding inhibitor),
DAD1 (defender against cell death) and NME-2 (non-
metastatic cell 2 antigen) as well as the transcription
factor genes EGR-1, GATA2 and CJUN.
Alternatively, it is possible to construct custom-made
microarrays tailored to suit specific investigations. To investi-
gate gene expression in prostate cancers, Carlisle et al [79]
constructed a microarray comprising 5,184 different cDNAs
selected from the 35,000 prostate cDNA library-derived
ESTs present in the database at the National Center for
Biotechnology Information (Table 1). cDNAs for microarrays
can also be preselected by cDNA subtraction. This
approach was used by Villaret et al [80] to identify new
tumour markers and vaccine candidates for head and neck
squamous cell carcinomas (HNSCCs). A subtracted library
enriched for expression in HNSCCs was prepared and
arrayed on glass slides. When the slides were probed simul-
taneously with fluorescently labelled probes prepared from
primary HNSCC and from control tissues, the differentially
overexpressed genes identified included those for keratins 6
and 16, laminin-5, plakophilin-1, matrix metalloproteinase-2,
vascular endothelial growth factor, connexin 26, 14-3-3
sigma, CaN19, and four previously unidentified genes. A
similar approach has been used to identify genes that are dif-
ferentially expressed in human prostate cancer [81]. Yang et
al [82] combined suppression subtractive hybridisation
(SSH) with microarray technology to identify differentially
expressed genes in ER-positive (MCF-7 and T47D) and ER-
negative (MDA-MB 23 and HBL100) breast cancer cell
lines. SSH is based on the technique of representational dif-
ference analysis (RDA) but modified to analyse mRNA abun-
dance. SSH was first performed using ER-positive MCF-7
mRNA as a ‘tester’ and ER-negative MDA-MB-231 cDNA as
a ‘driver’. A set of 332 cDNA clones which should be
enriched for genes overexpressed in MCF-7 cells compared
to MDA-MB-231 cells was identified and arrayed. When
microarrays were hybridised to probes prepared from ER-
positive and ER-negative breast cell lines, 10 clones were
found to be overexpressed at least fivefold in ER-positive
cells. The sequences included those for cytokeratin 19,
GATA3, CD24 and glutathione-S-transferase γ-3, as well as
several EST sequences and novel genes.
Similar approaches usually comparing tumour and normal
tissue and sometimes incorporating cDNA subtraction
have been used to examine progression in lung cancer
[83], rhabdomyosarcoma [84,85], ovarian cancer [86],
kidney cancer [87], melanoma [88], prostate cancer [78],
Ewing’s sarcoma [89] and colon cancer [33].
Microarrays and developmental biology
Microarrays are powerful tools for dissecting programmes
of organogenesis. Li et al [90] have investigated the role
of the mouse homeobox gene GSH1, which is expressed
in discrete domains in the ganglionic eminences, dien-
cephalon and hindbrain during brain development. Trans-
genic mouse technology was first used to construct
immortal GSH1–/– null cell lines from developing brain
cells that normally express GSH1. The GSH1 gene was
then reintroduced into the cells, and Affymetrix
GeneChips were used to monitor alterations in gene
expression. When 15 apparently differentially expressed
genes were examined in northern blot analyses, around
half appeared to represent display artefacts. Genes
whose altered expression was confirmed included the pro-
α2 (I) collagen gene, which was downregulated, and the
PBX1 homeobox gene, GAS1 (growth arrest specific 1)
and ceruloplasmin genes, which were upregulated.
Lee et al [91] used microarrays to investigate the mecha-
nism of action of the WT1 Wilms’ tumour gene during
kidney development. When introduced into U20S
osteosarcoma cells, the WT1(+KTS) isoform induced
apoptosis after 48 h, an effect that was not observed for
the WT1(–KTS) isoform. Further analysis of alteration of
gene expression induced by the WT1(+KTS) isoform
using a 6,800 gene microarray identified 12 genes and
ESTs that were upregulated, four of which were confirmed
by northern analysis. The most striking alteration was a 74-
fold induction of the amphiregulin gene which was accom-
panied by lower low levels of induction were observed for
HSP70, P21CIP1 and the gene for acidic fibroblast
growth factor. Subsequent analysis showed that the in
vivo expression profile of amphiregulin mirrors the pattern
of WT1 expression, that the WT1(+KTS) isoform can bind
directly to the amphiregulin promoter, and that, in primary
cultures of embryonic mouse kidney, amphiregulin can
stimulate epithelial branching. These studies strongly indi-
cate that a major role of WT1 is to act as a transcriptional
activator of amphiregulin.
Work carried out by Phillips et al [92] demonstrated the
way in which microarrays can be used to identify genes
specifically expressed in stem-cell populations. A cDNA
library from which housekeeping genes had been sub-
tracted was first prepared from mouse fetal liver, the first
tissue in development to contain significant numbers of
haematopoietic stem cells. The library of 18,000 clones
was then arrayed onto nylon membranes and genes that
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were differentially expressed either in fetal haematopoietic
stem cells or adult bone marrow stem cells were identified
by a variety of screening strategies. Four genes, including
CD27 and three novel sequences, were overexpressed in
both fetal and adult stem cells. Sets of genes that were
predominant in either fetal or adult hematopoietic cells
were also identified. The cytosine methyltransferase gene
Dnmt-3b and the variant histone gene macroH2A1.2
were, for example, highly overexpressed in fetal stem cells.
The use of microarrays in gene cloning
Microarray technology may be used to assist in positional
cloning projects as illustrated by the recent identification
of the gene responsible for insulin resistance in the spon-
taneously hypertensive rat strain SHR [93]. To identify
genes differentially expressed between SHR and insulin-
sensitive controls, microrrays of rat cDNA clones were
hybridised to targets from adipose tissue from the SHR
strain, a congeneic SHR.4 strain and the parent BN strain.
These experiments pinpointed clones encoding rat CD36
that showed substantially reduced hybridisation signals in
the SHR strain. CD36 mapped to the region of rat chro-
mosome 4 associated with insulin resistance and
encoded a fatty acid translocase, and its encoded product
was completely missing from the SHR adipocyte plasma
membrane. It was concluded from these studies that
CD36 was the gene whose alteration was responsible for
the insulin resistance.
The use of microarrays in toxicology
Microarray technology can, in principle, be used to study
the toxicology of anticancer drugs and of environmental
and dietary agents potentially involved in cancer develop-
ment [97,98]. To facilitate these analyses, a so-called
‘ToxChip’ has been developed that contains most of the
human genes known or proposed to be involved in toxico-
logical responses. These include DNA replication and
repair genes, apoptosis genes and genes involved in cellu-
lar responses to polycyclic aromatic hydrocarbons
(PAHs), dioxins, peroxisome proliferators, oestrogenic
compounds and oxidants. The goal of these studies is to
identify the patterns of alteration of gene expression char-
acteristic of exposure to each class of toxicant in cultured
human cells. Once signatures are identified, the patterns
of altered gene expression induced by unknown agents
might identify their likely mechanism of action. This
approach could also be applied, with the equivalent rat or
mouse gene arrays, to the investigation of responses to
toxicants in rodent models. The aim would be to identify
signatures for various types of tissue-specific toxicants,
providing a more rapid test for the possible toxicological
effect of drugs and less need to use animals.
It has been proposed that microarray profiling could be
used to monitor environmental exposure to chemicals in
humans. The rationale is that, as gene expression is a sen-
sitive end-point, alterations in microarray expression pro-
files may act as useful biomarkers to define more precisely
the nature and level of exposure to hazardous chemicals.
Gene expression profiles in an exposed individual would
be compared to control samples taken before exposure,
for example, in an occupational health setting. Studies are
currently underway to apply this approach to monitoring
gene expression in peripheral blood in potential cases of
extreme exposure to chemical toxicants, such as Polish
coke oven workers.
Amplification of mRNAs for microarray
analysis
A problem with mRNA profiling by microarray is that up to
200 µg of total RNA or 5 µg of poly(A)+ RNA may be
required to determine an expression profile, making analy-
sis of small tumour lesions extremely difficult. In some
cases, many smaller lesions can be pooled to make
enough RNA. Amplification of poly(A)+ RNA or cDNA can
in principle increase detection by orders of magnitude
[4,94–96]. For example, Wang et al [96] have developed
a procedure to optimise amplification of small RNA
samples. First, a 5′ reverse transcriptase primer containing
the T7 promoter sequence fused upstream of an oligodT
sequence together with template switching is used to
generate full-length cDNA molecules from the template
RNA. Next, many hundreds of antisense RNA molecules
are generated from each cDNA molecule using T7 poly-
merase. Finally, the antisense RNA is reverse transcribed
to produce fluorescently labelled cDNA that is hybridised
to the microarray. One round of this amplification yielded a
103-fold amplification, and two rounds yielded 105-fold
amplification. The microarray expression profiles obtained
with amplified RNA were comparable to those obtained
with the original RNA.
Conclusions
Microarray technology is a versatile technique that can be
used in a rich diversity of approaches to help understand
cancer development, to improve patient treatment and
management, and to identify those predisposed to
develop cancer. Although 50,000 genes may be present
in the human genome, the function of only around 10,000
has currently been established. A top priority must there-
fore be to construct microarrays that include all human
genes. The power of microarray technology is that it
allows global analysis of patterns of simultaneous gene
expression. This can identify novel gene–gene interactions
or enable entire control pathways to be followed, for
example. It is particularly powerful when the database of
expression patterns obtained using one microarray is
linked to other databases. Microarray expression patterns
could be integrated on the one hand with clinical data to
identify new markers to predict biological behaviour of
tumours, and on the other hand with databases of drug
sensitivity to unravel the molecular basis of drug action.
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Microarray data may also be used in conjunction with the
new technique of tissue array to enable the expression of
individual genes in hundreds of histopathological cancer
specimens to be examined [99]. With the vast amount of
work still to be done, microarray technology will have an
increasingly important role in the post-genomic era and
will most certainly be an essential player in the post-
genomic era.
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